Global Premenstrual Syndrome Treatment Market Set to Reach $1.91 Billion by 2033

Premenstrual Syndrome Treatment Market Overview

According to Renub Research Latest Report Premenstrual Syndrome (PMS) Treatment Market is projected to grow from USD 1,385.44 million in 2024 to USD 1,909.67 million by 2033, reflecting a CAGR of 3.63% from 2025–2033. This growth is propelled by increased awareness of women’s health, rising PMS prevalence, innovations in hormonal and non-hormonal therapies, and higher demand for effective treatments worldwide.

PMS treatments encompass hormonal therapies (oral contraceptives, ovarian suppression agents), antidepressants (SSRIs), NSAIDs, diuretics, and lifestyle interventions such as diet, exercise, and stress management. With growing attention to women’s reproductive health, PMS management is becoming a crucial part of modern healthcare.

👉 Want to explore detailed market trends, segment insights, and forecasts? 🔗 Request Sample Report

Key Growth Drivers

1. Increasing Awareness and Education on Women’s Health

Global awareness campaigns, social media outreach, and government initiatives are educating women about PMS symptoms and treatment options. Early medical consultation and proper diagnosis lead to higher adoption of both pharmaceutical and non-pharmaceutical interventions. According to the National Institutes of Health (NIH), approximately 75% of women experience PMS symptoms, and around 5% suffer from severe PMDD, driving the need for effective treatment options.

2. Advances in Pharmaceutical and Non-Pharmaceutical Therapies

Innovations in SSRIs, combination oral contraceptives, NSAIDs, and herbal supplements are enhancing treatment efficacy and patient satisfaction. For instance, in September 2023, Vistagen reported promising Phase 2A results for PH80, aimed at treating acute PMDD symptoms. This combination of prescription drugs, lifestyle therapies, and OTC supplements allows personalized care plans, boosting market adoption.

3. Expanded Healthcare Access and Urbanization

Improved healthcare infrastructure in emerging markets, combined with urbanization, telemedicine, and insurance coverage, has increased access to PMS treatments. Women in urban areas are more likely to seek medical advice, use OTC remedies, or get prescriptions filled through hospital pharmacies and retail outlets.

Challenges in the PMS Treatment Market

1. Limited Diagnosis in Developing Regions

PMS remains underdiagnosed in rural and underserved regions due to cultural taboos, lack of gynecological care, and low awareness. Poor healthcare infrastructure restricts access to advanced therapies and limits market growth in these areas.

2. Side Effects and Compliance Issues

Prescription therapies, such as SSRIs and hormonal contraceptives, may cause weight gain, nausea, or mood changes, reducing patient compliance. Non-pharmaceutical treatments, while safer, may be less effective. Chronic PMS symptoms require ongoing management, making adherence a key challenge.

👉 For deeper analysis, detailed segment data, and company insights: 🔗 Request Customization Report

Market Segmentation

By Drug Type

Analgesics (NSAIDs like ibuprofen and naproxen)

Antidepressants (SSRIs)

Oral Contraceptives and Ovarian Suppression Agents

Others (supplements, herbal remedies)

By Type

Prescription

Over-the-Counter (OTC)

By Distribution Channel

Hospital Pharmacies

Drug Stores and Retail Pharmacies

Online Stores

By Region

North America: United States, Canada

Europe: France, Germany, Italy, Spain, UK, Belgium, Netherlands, Turkey

Asia Pacific: China, Japan, India, South Korea, Thailand, Malaysia, Indonesia, Australia, New Zealand

Latin America: Brazil, Mexico, Argentina

Middle East & Africa: Saudi Arabia, UAE, South Africa

Regional Insights

United States

The U.S. leads the PMS treatment market due to high awareness, advanced healthcare infrastructure, strong retail pharmacy networks, and prescription drug adoption. In March 2024, Pfizer launched Loryna, an innovative oral therapy for PMDD, addressing unmet medical needs in women with severe PMS.

France

France benefits from comprehensive healthcare access, progressive women’s health policies, and well-established pharmacy networks. Hormonal therapies and analgesics are widely used, with increasing awareness of PMDD driving prescription demand.

China

Urbanization, growing awareness, and access to gynecological services fuel PMS treatment growth. OTC analgesics dominate, but prescription treatments are rising in tier-one cities. Government initiatives and digital health platforms enhance diagnosis and treatment adoption.

Brazil

Increasing reproductive health awareness drives PMS treatment adoption, primarily through urban pharmacies. Telemedicine and online pharmacy platforms are extending reach to underserved rural areas.

Saudi Arabia

Healthcare modernization under Vision 2030 has boosted PMS treatment adoption. Hospital pharmacies and retail outlets ensure access to prescription and OTC treatments, while rising urbanization and cultural shifts support market expansion.

Key Players

AbbVie Inc. – Hormonal therapies and SSRIs

BASF SE – Nutritional supplements

Bayer AG – Oral contraceptives

Dr. Reddy’s Laboratories Ltd – Prescription and OTC treatments

Eli Lilly and Company – Antidepressants

GlaxoSmithKline Plc. – OTC remedies and supplements

H. Lundbeck A/S – SSRIs and novel therapeutics

Pfizer Inc. – PMDD and PMS therapies

SHIONOGI & Co. Ltd. – Specialty treatments

These companies drive the market through product innovation, global distribution, and awareness campaigns, targeting both mild PMS symptoms and severe PMDD cases.

Conclusion

The Premenstrual Syndrome Treatment Market is projected to grow steadily through 2033, driven by women’s health awareness, urbanization, access to healthcare, and pharmaceutical innovation.

While diagnosis gaps in developing regions and treatment compliance challenges persist, the increasing availability of prescription and OTC treatments, lifestyle interventions, and hospital-based care ensures that PMS management remains a key priority in global women’s healthcare.

Note: If you need details, data, or insights not covered in this report, we are glad to assist. Through our customization service, we will collect and deliver the information you require, tailored to your specific needs. Share your requirements with us, and we will update the report to align with your expectations.